Impact of baseline <sup>18</sup>F-flotufolastat PET bone tumor volume for prognosticating severe hematologic toxicity in patients with metastatic castration-resistant prostate Cancer receiving <sup>177</sup>Lu-PSMA-targeted radioligand therapy.

Eur J Nucl Med Mol Imaging · 2025 · PMC12491086 · PMID 40383857

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

However, in the multivariate analysis, osseous TV was outperformed by baseline laboratory parameters and did not reach statistical significance.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.

Impact of baseline &lt;sup&gt;18&lt;/sup&gt;F-flotufolastat PET bone tumor volume for prognosticating severe hematologic toxicity in patients with metastatic castration-resistant prostate Cancer receiving &lt;sup&gt;177&lt;/sup&gt;Lu-PSMA-targeted radioligand therapy.

The sentences

Impact of baseline <sup>18</sup>F-flotufolastat PET bone tumor volume for prognosticating severe hematologic toxicity in patients with metastatic castration-resistant prostate Cancer receiving <sup>177</sup>Lu-PSMA-targeted radioligand therapy.